IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is an oncofetal protein whose expression is prognostic for poor outcome in several cancers. Although IMP3 is expressed preferentially in triple-negative breast cancer (TNBC), its function is poorly understood. We observed that IMP3 expression is significantly higher in tumor initiating than in non-tumor initiating breast cancer cells and we demonstrate that IMP3 contributes to self-renewal and tumor initiation, properties associated with cancer stem cells (CSCs). The mechanism by which IMP3 contributes to this phenotype involves its ability to induce the stem cell factor SOX2. IMP3 does not interact with SOX2 mRNA significantly or regulate SOX2 expression directly. We discovered that IMP3 binds avidly to SNAI2 (SLUG) mRNA and regulates its expression by binding to the 5' UTR. This finding is significant because SLUG has been implicated in breast CSCs and TNBC. Moreover, we show that SOX2 is a transcriptional target of SLUG. These data establish a novel mechanism of breast tumor initiation involving IMP3 and they provide a rationale for its association with aggressive disease and poor outcome.
INTRODUCTION
Many cancers harbor a small population of cells, often referred to as cancer stem cells (CSCs), which exhibit the ability to self-renew and initiate new tumors. 1, 2 These characteristics have important implications for our understanding of tumor recurrence and dormancy. 2 Despite the evidence supporting the existence of CSCs, much less is known about the origin of these cells and the mechanisms that regulate their function. The concept that solid tumors contain stemlike cells was pioneered in breast cancer and subsequent studies have used breast cancer as a model to study the genesis of CSCs. 1, 3 Triple-negative breast cancers (TNBCs) are of particular interest in this discussion because these aggressive cancers harbor a relatively highfrequency of CSCs compared with other breast cancer subtypes. 3 For these reasons, TNBCs are useful for elucidating mechanisms that contribute to the formation and function of CSCs. In this context, we are interested in IMP3, which is a member of a family of IGF2 mRNA binding proteins that function in RNA stabilization, trafficking and localization, 4 because it is expressed preferentially in TNBC. 5 These observations are consistent with the fact that IMP3 expression correlates with the aggressive behavior of many cancers and that it has been exploited for the prognostic assessment of specific cancers. 6 What is not known is whether there is a causal link between IMP3 and aggressive behavior and, if so, the mechanism by which this RNA binding protein contributes to such behavior.
In this study, we pursued the potential contribution of IMP3 to breast CSCs and TNBC and sought to investigate the mechanisms involved.
RESULTS
IMP3 expression is elevated in breast CSCs and contributes to self-renewal and tumor initiation Analysis of a published gene expression profile 7 revealed that IMP3 expression is significantly higher in the tumor initiating
CD44
+ CD24
− ESA + population 1 isolated from human breast tumor tissues compared with the bulk population of tumor cells ( Figure 1a ). There was no significant difference in the expression of IMP1 and IMP2 (two other members of the IGF2 mRNA binding protein family) between these populations (Figure 1a ). On the basis of this observation and the report that IMP3 is preferentially expressed in TNBCs, 5 we assessed the contribution of IMP3 to the genesis and function of the CD44 Given that mammosphere culture can increase the frequency of breast CSCs, 8 we characterized mammosphere-derived cells for their expression of stem cell markers and frequency of CD44 + CD24
− ESA + cells. For this purpose, we used SUM1315 cells and patient-derived xenografts of TNBC, 9 which express IMP3 (Supplementary Figure S1C 
CD24
-ESA + cells, are significantly elevated in mammospheres generated from these cells compared with adherent cells. Importantly, collagen-1-induced differentiation of mammosphere-derived patient-derived xenograft cells resulted in a decrease in IMP3 expression and in the frequency of CD44 + CD24
− ESA + cells (Supplementary Figure  S1D) . This observation is strengthened by our analysis of SUM159 and T47D cells, which do not express IMP3 when grown as adherent cultures. Interestingly, IMP3 expression is induced significantly in these cells when grown as mammospheres, and collagen-1 induced differentiation of these mammospheres retain the lipophilic dye PKH26, a measure of the quiescent nature of CSCs (Figure 1f ). 3 Elevated expression of IMP3 in mammospheres and its reduction upon collagen-induced differentiation suggests that IMP3 may regulate the mammosphere forming ability of TNBC cells. Indeed, depletion of IMP3 expression in SUM1315 cells and cells isolated from a human breast tumor decreased their ability to form mammospheres (Figure 2a, Supplementary Figure S1E ). The ability of IMP3-depleted cells to form mammospheres was restored upon transfection of IMP3-depleted SUM1315 cells with an IMP3 expressing construct that is resistant to shIMP3-1 (IMP3-mut), demonstrating the specificity of IMP3 (Figure 2b ). Moreover, IMP3 depletion specifically in the CD44 + CD24
− ESA + population isolated from SUM1315 cells also decreased mammosphere formation ( Figure 2c ). Given that self-renewal is a defining feature of stem cells, we assessed the role of IMP3 in self-renewal by quantifying the ability of mammospheres to be passaged serially. As shown in Figure 2d , depletion of IMP3 significantly reduced the number of mammospheres with increasing passage. The ability of IMP3 to regulate self-renewal and the frequency of CD44 +
− ESA + cells suggested that it contributes to tumor initiation. Indeed, transplantation of IMP3-depleted SUM1315 cells in the mammary fat pads of non-obese diabetic-Cg-Prkdc scid IL2rg tm1Wjl (NSG) mice significantly increased tumor-free survival compared with control cells (Figure 2e , left panel). Tumor initiating ability was restored by transfecting IMP3-depleted cells with the IMP3-expressing construct that is resistant to the shRNA (IMP3-mut) (right panel). 
− ESA + and bulk populations of breast tumor cells using a published database (GEO accession no. GSE6883). Gene expression was analyzed in GEO2R. (b) IMP3 expression was depleted using shRNAs (shIMP3-1 and shIMP3 -2) 
−/low population comprises distinct epithelial and mesenchymal populations, which differ markedly in their tumorigenic properties. 12 Specifically, the mesenchymal population is highly tumorigenic and enriched for breast CSCs compared with the epithelial population. We observed that the expression of IMP3, but not IMP1 and IMP2, is significantly higher in the mesenchymal population of CD44 +
− /low cells compared with the epithelial population and that depletion of IMP3 in the mesenchymal cells reduced their selfrenewal ability (Figures 2f and g ). Taken together, our data demonstrate that IMP3 promotes self-renewal and tumor initiation.
IMP3 regulation of SOX2 underlies its contribution to mammosphere formation To investigate the mechanism by which IMP3 contributes to mammosphere formation and tumor initiation, we focused initially on SOX2 for several reasons. Its expression is enhanced in mammospheres ( Figure 1c ) and it has been implicated in the genesis of TNBC. 13 Moreover, SOX2 expression is associated with basal-like breast cancers, 14 the majority of which are triplenegative and harbor a high frequency of tumorigenic cells. 15 These observations suggest a causal link between IMP3 and SOX2. Indeed, we found that SOX2 expression is elevated in CD44 +
− ESA + cells and in the mesenchymal population isolated from SRC-transformed MCF10A cells (Figure 3a) . Moreover, SOX2 expression increases in mammosphere culture and decreases upon differentiation of these cells (Figure 3b ). The observed 
ESA
+ population sorted from SUM1315 cells and the mesenchymal population of SRCtransformed MCF10A cells, and SOX2 mRNA was quantified by qPCR. (e) IMP3 and SOX2 expression was quantified by qPCR in SKBR3 cells transiently transfected with an empty vector or IMP3 expression construct (pIMP3). (f) SOX2 expression was rescued in IMP3-depleted SUM1315 cells (shIMP3-1 and shIMP3-2) using a lentivirus-based expression construct (pSOX2, left). These IMP3-depleted and SOX2 rescued cells were grown as mammospheres for 7 days and quantified (right). (g) SOX2 expression was depleted in SUM1315 cells using shRNAs (shSOX2-1 and shSOX2-2, left) and these cells were evaluated for mammosphere formation in comparison with control cells (right). (h) SOX2 expression and mammosphere formation were evaluated using IMP3-depleted and IMP3-depleted cells that had been transfected with wildtype IMP3 (IMP3-wt) or a mutant construct that is resistant to shIMP3-1 (IMP3-mut). (i) RIP was performed on extracts prepared from SUM1315 cells using an IMP3-specific antibody or isotype matched IgG. SOX2, NANOG and IGF2 mRNAs were quantified by qPCR. IGF2 mRNA was used as a positive control and NANOG was used as a negative control. Immunoblot shows the specificity of IMP3 antibody. P-value (*)o0.05.
IMP3 promotes breast cancer stem cell function S Samanta et al IMP3 to promote mammosphere formation is SOX2 dependent. Moreover, depletion of SOX2 in SUM1315 cells significantly reduced mammosphere formation compared with control cells (Figure 3g ). Importantly, transfection of IMP3-depleted SUM1315 cells with the shRNA-resistant IMP3 construct increased SOX2 expression and mammosphere formation (Figure 3h ), providing specificity for IMP3 regulation of SOX2. Interestingly, BMI1, which has been implicated in self-renewal, 16 is not regulated by IMP3 (Supplementary Figure S2D) . Since IMP3 was originally identified as IGF2 binding protein and that IGF2 promotes tumor formation, 17 we explored the possible contribution of IGF2 to SOX2 expression. Depletion of IGF2 did not alter SOX2 mRNA expression even though IMP3 regulates the expression of IGF2 (Supplementary Figure S2E) . Collectively, our data demonstrate that IMP3 contributes to mammosphere formation by regulating SOX2.
In pursuit of the mechanism by which IMP3 regulates SOX2, we performed an RNA-immunoprecipitation (RIP) assay to determine whether IMP3 can bind to SOX2 mRNA directly. As shown in Figure 3i , we detected modest binding of IMP3 to SOX2 mRNA compared with IGF2 mRNA. Given that IMP3 usually binds to the 3' or 5' UTR of its target mRNAs, we generated reporter constructs in which luciferase mRNA was fused with either the 3'UTR or the 5'UTR of SOX2. Transfection of these constructs into control (empty vector) or IMP3-expressing (pIMP3) SUM159 cells resulted in no significant changes in luciferase activity, diminishing the possibility of a direct interaction between IMP3 protein and SOX2 mRNA (Supplementary Figure S2F) . SLUG phenocopies the functions of IMP3 SLUG (SNAI2) is a zinc-finger transcription factor, expressed preferentially in poorly differentiated breast cancers and it has been implicated in the function of breast CSCs and the initiation of basal-like breast cancer. [18] [19] [20] On the basis of these observations, we hypothesized that SLUG and IMP3 function in concert. We observed elevated expression of SLUG in CD44 +
CD24
− ESA + cells isolated from human breast tumors compared with the bulk population (Figure 4a ) in the same data set that we used to analyze IMP3. 7 SLUG expression is also elevated in CD44 + CD24 − ESA + cells isolated from TNBC cell lines (Figure 4b ). Moreover, SLUG expression is enhanced by mammosphere culture and repressed by collagen-I-induced differentiation of these cultures (Figure 4c ). These similarities between IMP3 and SLUG coupled with the previous report that SLUG can induce SOX2 expression in hepatocellular carcinoma cells prompted us to investigate whether SLUG can also regulate SOX2 expression in TNBC. 21 In fact, we found that depletion of SLUG in TNBC and human breast tumor cells decreased SOX2 expression and mammosphere formation (Figure 4d, Supplementary Figure S2G The parallels between IMP3 and SLUG expression and function prompted us to investigate the possibility that IMP3 regulates SLUG expression and that SLUG mediates the contribution of IMP3 to tumor initiation. In fact, IMP3 was shown recently to regulate SLUG expression by binding to its mRNA and SLUG rescue in IMP3-depleted TNBC cells restored their migration and invasive ability. These data implicate SLUG as an important functional target of IMP3. 22 We confirmed this finding and demonstrated that IMP3 binds to the 5'UTR of SLUG mRNA (Figure 5a and Supplementary Figures S3A and C) . Moreover, we found that IMP3 can regulate SLUG expression in CD44 + CD24 − ESA + cells (Figure 5b) . IMP2, however, does not appear to impact SLUG expression ( Figure 5c ) and no correlation between IMP2 and SLUG was detected in a gene expression dataset (Figure 5d ). [23] [24] [25] SLUG depletion did not affect IMP3 expression, indicating that SLUG functions downstream of IMP3 ( Supplementary Figures S3D and E) . Collectively, our data demonstrate that IMP3 can regulate SLUG expression and that SLUG functions downstream of IMP3.
The above findings prompted us to interrogate whether SLUG mediates IMP3 regulation of SOX2 and tumor initiation. Expression of SLUG in IMP3-depleted SUM1315 cells, which express low levels of SLUG, rescued SOX2 expression (Figure 5e ) and increased the CD44 + CD24
− ESA + population (Figure 5f ). Moreover, IMP3 expression in SKBR3 cells that had been pre-transfected with SLUGspecific shRNA failed to induce SOX2 expression (Figure 5g ). These findings demonstrate that SLUG mediates the IMP3 regulation of SOX2 expression. This conclusion was substantiated in vivo by showing that expression of SLUG in IMP3-depleted SUM1315 cells increased their tumor initiating ability (Figure 5h ). The role of the IMP3/SLUG axis in breast CSCs is also supported by our analysis of a published gene expression profile of doxorubicin-resistant subline derived from MCF7 cells, a luminal breast cancer cell line. These drug-resistant cells are highly enriched for the tumor initiating CD44 + CD24 −/low population and are much more tumorigenic than parental MCF7 cells. 26 Interestingly, these drug-resistant cells were found to be slow cycling and express much higher levels of both IMP3 and SLUG compared with parental MCF7 cells (Supplementary Figure S3F) . Finally, we observed that the expression of IMP3, SLUG and SOX2 correlates in a breast cancer database (Figure 6a) . 27 Although most studies on SLUG in breast cancer have focused on its ability to repress transcription, 28, 29 our data suggest that it may contribute to the activation of SOX2 transcription. We detected several E-boxes (CAnnTG) 30 within the proximal region of the SOX2 promoter ( Figure 6b ) and chromatin immunoprecipitation analysis detected a significant enrichment of SLUG in the region containing E-box-3 (E3) at − 2093 bp. In contrast, we did not detect any SLUG binding in the E-boxes proximal or distal to E3 (Figure 6b ).
DISCUSSION
In this study, we implicate IMP3 in the function of breast CSCs in TNBC, and demonstrate that this function is mediated by IMP3 regulation of SLUG. This key conclusion provides a rationale for the observation that IMP3 is expressed preferentially in TNBC 5 because these tumors exhibit a high frequency of CSCs compared with other subtypes of breast cancer. 3 Our findings may also explain why IMP3 expression is prognostic for aggressive disease and metastatic potential based on the evidence that CSCs contribute to these clinical parameters. 6, 31 Our findings reveal a post-transcriptional mechanism of SLUG regulation mediated by IMP3. This mode of regulation may function in concert with mechanisms that regulate SLUG transcription to ensure that SLUG expression is tightly controlled in breast cancer, especially given its ability to promote the genesis of CSCs, basal differentiation and the genesis of basal-like breast cancer. 20, 32 However, the mechanisms that regulate SLUG expression in breast cancer had not been determined. Clearly, IMP3-mediated regulation of SLUG mRNA provides one such mechanism. Although we demonstrate that IMP3 contributes to the genesis and function of breast CSCs by regulating SLUG expression, it likely contributes to these processes in other ways as well. In this direction, we note the recent finding that IMP3-ribonucleoproteins function as 'cytoplasmic safe houses' that prevent miRNA-mediated mRNA decay of specific oncogenes. 33 A critical result is that SOX2 is a transcriptional target of SLUG establishing a causal relationship between two prominent factors IMP3 promotes breast cancer stem cell function S Samanta et al in the biology of CSCs. Although SOX2 is not expressed in normal mammary stem cells, recent studies have highlighted its importance in breast cancer and CSCs. [34] [35] [36] [37] The fact that IMP3 regulates SOX2 by a SLUG-dependent mechanism enhances the significance of this mRNA binding protein in CSCs and the initiation of TNBC. Moreover, both IMP3 and SOX2 are expressed in embryonic stem cells, and there is a considerable similarity in the gene expression signatures between TNBCs and embryonic stem cells. 31 In addition to its critical role in embryonic stem cells, SOX2 has also been shown to regulate self-renewal and tumor initiation in osteosarcomas and squamous cell carcinomas. 34, 38 Moreover, the epidermal growth factor receptor can regulate selfrenewal and CSC function by regulating SOX2. 39, 40 Interestingly, we reported that epidermal growth factor receptor regulates IMP3 expression in TNBC cells. 41 Our findings suggest that IMP3 could have a significant role in resistance to chemotherapy and that it could be an attractive candidate for targeted therapy itself. Chemoresistance is an important feature of CSCs, 42 which results from the elevated expression of several ABC (ATP-binding cassette) transporters including breast cancer resistance protein (BCRP/ABCG2) that is also regulated by IMP3. 43 In hepatocellular carcinoma, for example, IMP3 has been implicated in the abrogation of TGFβ signaling and consequent chemoresistance. 44 In contrast, both IMP3 43 and TGFβ signaling 45 have been implicated in the chemoresistance of TNBC cells, suggesting that IMP3 does not inhibit TGFβ signaling in TNBC. Moreover, the observation that IMP3 expression is elevated in slow-cycling drug-resistant cells that display CSC properties is significant because chemotherapeutic drugs typically target rapidly proliferating cells and residual disease is enriched in slow-cycling cells with a higher frequency of CSCs that may be responsible for metastasis and relapse. 7, 42 Targeting IMP3 is a potentially feasible and effective approach for the clinical management of TNBC because it is not expressed in normal breast and its mechanism of action is known (binding to specific RNA sequences). Also, as mentioned above, IMP3 contributes to residual disease following chemotherapy. The feasibility of targeting IMP3 is supported by the ability of IMP3-derived peptides to elicit a positive cytotoxic T lymphocyte response in patients with advanced esophageal cancer. 46 Interestingly, IMP2 has been implicated in the function of glioblastoma CSCs by a mechanism that involves regulation of key mRNAs involved in oxidative phosphorylation. 47 Although, both proteins are preferentially expressed in TNBCs, IMP2 did not appear to be important for the function of breast CSCs, partly because of its inability to regulate SLUG expression. Nonetheless, an emerging paradigm is that IMPs are critical for the function of CSCs and potential therapeutic targets. 44, 47 
MATERIALS AND METHODS

Cells and reagents
The human breast cancer cell lines SUM1315 and SUM159 were obtained from Dr Stephen Ethier (Kramanos Institute, MI, USA). MCF10A, MDA435, MDA468, SKBR3, BT549, T47D and HEK293T cell lines were obtained from American Type Culture Collection (ATCC). SUM1315 cells were maintained in F-12 medium supplemented with 5% fetal bovine serum (FBS), insulin (5 μg/ml), epidermal growth factor (10 ng/ml) and 1% penicillinstreptomycin. SUM159 cells were maintained in F-12 medium supplemented with 5% FBS, insulin (5 μg/ml), hydrocortisone (1 μg/ml) and 1% penicillin-streptomycin. The MDA468, MDA435, BT549, T47D and SKBR3 cell lines were maintained in RPMI supplemented with 10% FBS and 1% penicillin-streptomycin. HEK293T cells were cultured in DMEM (high glucose) supplemented with 10% FBS, non-essential amino acids (1 × , Life Technologies, Grand Island, NY, USA), HEPES (pH 7.4, 1 mM, Life Technologies), sodium pyruvate (1 mM, Life Technologies) and 1% penicillin-streptomycin. ER-SRC-transformed MCF10A cells was provided by Dr Kevin Struhl (Harvard Medical School) and maintained as described. 12 shRNAs specific for GFP (RHS4459), IMP3 (TRCN0000074675, TRCN0000074677), SLUG (TRCN0000015389, TRCN0000015390), SOX2 (TRCN0000003252, TRCN0000003250) and IGF2 (TRCN0000062430, TRCN0000062432) were obtained from Open Biosystems (Rockford, IL, USA). Smartpool siRNA specific for IMP3 and IMP2 was purchased from Thermo Scientific (Lafayette, CO, USA). Antibody for IMP3 was purchased from DAKO (Carpinteria, CA, USA). SLUG, SOX2 and BMI1 antibodies were purchased from Cell Signaling technology (Danvers, MA, USA). GAPDH and p84 antibodies were obtained from Genetex (Irvine, CA, USA). The luciferase reporter constructs PsiCheck-2 and pLightSwitch_5UTR were obtained from Dr Sean Ryder (UMass Medical School, Worcester, MA, USA) and SwitchGear Genomics (Carlsbad, CA, USA), respectively. Lipofectamine-2000 and Fugene-6 were procured from Life Technologies and Promega Corporation (Madison, WI, USA), respectively. Collagen-1 was purchased from BD Biosciences (San Jose, CA, USA).
Antibodies used for FACS are CD44-PE, CD24-APC (BD Biosciences); mouse-ESA (AbCam, Cambridge, MA, USA) and anti-mouse-488 (AbCam).
IMP3, SLUG and SOX2-depleted cell lines were generated by infecting them with pLKO.1-based lentiviruses expressing the corresponding shRNAs and subsequent selection in puromycin (2 μg/ml). Stable cell lines were maintained regularly in puromycin (1 μg/ml). IMP3 and SLUG expression constructs were generated by inserting their cDNAs into a lentivirus vector (pCDH-CMV-MCS-EF1-copGFP) into EcoRI/NotI and EcoRI/BamHI sites respectively. Primers used are listed in Supplementary Table 1. Human breast tumor tissue Human breast tumor tissue was obtained in compliance with the Institutional Review Board of the University of Massachusetts Medical School. Tumor cells were isolated as described previously. 48 Briefly, the tissue was minced and digested for 6 h with a mixture of collagenase-A (Roche, Indianapolis, IN, USA) and hyaluronidase (MP Biomedicals, Solon, OH, USA). The digested cells were spun down, washed twice with serum-free DMEM/F12 medium and resuspended cells were plated in complete medium (DMEM/F12, 10% FBS, 1% penicillinstreptomycin and 5 μg/ml insulin) for 2 h to deplete mammary fibroblasts. The collected organoids were dissociated into a single cell suspension by trypsinization and filtered through 40 μm filter (BD Biosciences) to remove residual clustered cells and plated for subsequent experiments.
Patient-derived xenograft
Breast tumor tissue (triple-negative) samples were obtained from breast cancer surgery patients, through Brigham and Women's Hospital and Massachusetts General Hospital. These breast tumors samples were cut into small fragments, which were then surgically implanted into the fourth mammary fat pad of NSG mice. Tumor xenografts were expanded into multiple recipient NSG mice for several passages. Tumors were harvested and analyzed as described in the text. 
ESA
+ population, cells were incubated with the same antibodies, resuspended in serum-free DMEM-F12 (1:1) with 1 mM EDTA and collected in same medium with 10% FBS. All analyses were performed using BD LSRII flow cytometer (BD Biosciences) and data analysis were performed using the FlowJo software (FlowJo, LCC, Ashland, OR, USA).
Mammosphere, self-renewal and tumor initiation experiment Mammospheres were cultured as described previously. 49 For self-renewal assays, mammospheres were collected by centrifugation, washed with phosphate-buffered saline, trypsinized for 5 min and single cell suspension was prepared. This single cell suspension was counted and seeded for subsequent mammosphere formation. Mammospheres were counted by taking bright-field images of 15-20 different areas per well. Differentiation was induced by culturing the mammosphere-derived cells on collagen-1-coated dish with serum containing medium. 10 Trypsin was inactivated by soybean-trypsin inhibitor (1 mg/ml, Sigma, St Louis, MO, USA).
For tumor initiation experiment, cells were mixed with matrigel (1:1,v/v) and 50 μL of the cell-matrigel mix was injected into the mammary fat pads of NSG mice (Jackson Laboratory, Bar Harbor, ME, USA) as described previously. 49 Tumor onset was determined by palpation and visual observation.
PKH26 labeling
For PKH26 staining, control and IMP3-depleted SUM1315 cells were stained with PKH26 Red Fluorescent Cell Linker Kit (Sigma). Labeled cells were maintained for 3 weeks and PKH26 + cells were quantified using FACS. 7-Aminoactinomycin-D was used to discriminate dead cells. The same procedure was followed to sort PKH26 + population from MDA435 cells.
Biochemical assays
For immunoblotting, cell extracts were prepared using RIPA buffer containing EDTA and EGTA (Boston Bioproducts, Ashland, MA, USA). Cytoplasmic and nuclear extracts were prepared using NE-PER Nuclear and Transfections and reporter assays Transient transfection of IMP3 and SLUG expression constructs was performed using Fugene-6 as the transfection agent, and total mRNA and protein extracts were prepared 48 h post transfection. siRNAs specific to IMP3 and IMP2 (25 nM) were transfected using Dharmafect-4 (Thermo Scientific) as the transfection agent and protein extracts were prepared 72 h post transfection. For siRNA experiments, a pool of non-targeting siRNA (Thermo Scientific) was used as a control (25 mM).
To generate SOX2 and SLUG 3'/5' UTR reporter constructs, human SOX2 or SLUG 3' UTR and 5' UTR were amplified using cDNA prepared from SUM1315 cells and cloned into the psiCheck-2 and pLightSwitch-5'UTR vectors, respectively. The 3'UTR was cloned into XhoI/NotI sites and the 5' UTR was cloned into BglII/NcoI sites. Same restriction sites were used for both SLUG and SOX2 UTRs. PCR-amplified UTR fragments were confirmed by restriction mapping and cloned reporter constructs were confirmed by sequence analysis. Primers used are listed in Supplementary Table 3 CACCTG -568bp Figure 6 . SLUG binds to the SOX2 promoter. (a) IMP3, SLUG and SOX2 mRNA expression was correlated in a published database comprising 327 samples (GEO accession no. GSE6532). Statistical significance was determined using Pearson's correlation. (b) Chromatin immunoprecipitation (ChIP) was performed using genomic DNA isolated from SUM1315 cells using a SLUG-specific antibody, and the SLUG-bound SOX2 fragments were quantified by qPCR. Isotype matched IgG was used as a control for this experiment. A construct expressing firefly luciferase (PGL3 control vector) was used as a transfection control. The relative luminescence unit (RLU) was determined as renilla luciferase normalized to firefly luciferase activity. (b) SLUG mRNA was quantified by qPCR using total RNA prepared from IMP3-depleted CD44 + CD24 − ESA + population sorted from SUM1315 cells (left) and the mesenchymal CD44 + CD24 − population of Src-transformed MCF10A cells (right). (c) Expression of IMP2 and SLUG was measured by qPCR using total RNA extracted from control or IMP2-depleted SUM1315 cells. IMP2 was depleted using smart-pool siRNA (20 nM) and transfection was carried out using Dharmafect-4 for 72 h. An off-target siRNA pool (20 nM) was used as a control. (d) Expression of IMP3, IMP2 and SLUG was correlated using a published gene expression database comprising 81 BLBCs (cBioportal). Correlation coefficient (r) was calculated using Pearson's correlation. (e) IMP3-depleted SUM1315 cells (shIMP3-1 and shIMP3-2) were transiently transfected with either an empty vector or a SLUG expression construct (pSLUG). SLUG and SOX2 mRNA expression was quantified by qPCR. (f) IMP3-depleted SUM1315 cells (shIMP3-1) were transiently transfected with either an empty vector or a SLUG expression construct and these cells were used to quantify CD44 + CD24 − ESA + population by FACS (right). IMP3 and SLUG expression was measured by qPCR (left). (g) SKBR3 cells pre-transfected with either control shRNA (shControl) or SLUG-specific shRNAs (shSLUG-1 and shSLUG-2) were transfected with an empty vector or IMP3-expressing construct. RNA isolated from these cells was used to quantify IMP3, SLUG and SOX2 expression by qPCR. (h) Control, IMP3-depleted or IMP3-depleted SUM1315 cells, stably infected with a SLUG-expressing lentivirus construct, were mixed with Matrigel (1:1, v/v) and injected into the mammary fat pads of NSG mice. Number of cells injected is indicated in the figure. Each group comprised seven mice. P-value (*)o0.05.
with either the control or UTR constructs. Firefly reporter construct was used as a transfection control for both 3' and 5' UTR constructs that express renilla luciferase. The relative light units value was calculated as the ratio of renilla luciferase to firefly luciferase activity (normalized luciferase activity). The protocol used for transfection and measurement of luciferase activity has been described previously. 50 Luciferase activity was measured in a DTX 880 luminometer (Beckman Coulter, Inc., Brea, CA, USA).
Binding assays
The interaction between IMP3 protein and associated mRNAs was determined using RIP assay followed by qPCR analysis. The assay was performed using RiboCluster Profiler RIP-Assay kit (MBL International, Woburn, MA, USA). RIP grade antibody for IMP3 was purchased from the same company. Isotype-matched IgG was used as a control for immunoprecipitation. The chromatin immunoprecipitation assay was performed using ChIP-IT Express kit (Active motif, CA, USA). Chromatin was prepared by sonication using MISONIX Sonicator-3000 (power level 2, 15 s pulse X 4). DNA fragments were amplified by qPCR. Primers are listed in Supplementary Table 4 .
Statistical analysis
The data are shown as ± s.e. P-values (*) were determined using Student's t-test and P ⩽ 0.05 was considered as significant. For in vivo serial dilution experiment, P-values were calculated using Extended Mantel-Haenszel Stratified Test of Association. For correlation studies, statistical significance was calculated by Pearson's correlation.
